Autolus Stock Analysis

AUTL -  USA Stock  

USD 7.57  0.05  0.66%

The new hike in Autolus Therapeutics short term price appreciation could raise concerns from stakeholders as the firm it trading at a share price of 7.57 on 2,091,400 in volume. The company directors and management have successfully maneuvered the firm at convenient times to take advantage of all market conditions in May. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.34. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Autolus Therapeutics partners.
Please continue to Trending Equities.

Search Stock Analysis 

The Autolus Therapeutics stock analysis report makes it easy to digest most publicly released information about Autolus Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Autolus stock analysis module also helps to analyze the Autolus Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Autolus Stock Analysis Notes

About 26.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.25. Some equities with similar Price to Book (P/B) outperform the market in the long run. Autolus Therapeutics Plc recorded a loss per share of 1.4. The entity had not issued any dividends in recent years. Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 376 people. For more info on Autolus Therapeutics Plc please contact the company at 44 20 3829 6230 or go to

Autolus Therapeutics Plc Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Autolus Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Autolus Therapeutics Plc or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Autolus Therapeutics has very high historical volatility over the last 90 days
Autolus Therapeutics has high likelihood to experience some financial distress in the next 2 years
The company reported the previous year's revenue of 1.08 M. Net Loss for the year was (53.28 M) with loss before overhead, payroll, taxes, and interest of (133.17 M).
Autolus Therapeutics Plc currently holds about 217.45 M in cash with (17.09 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 5.52.
Roughly 26.0% of the company shares are held by company insiders
Latest headline from Autolus Therapeutics plc - ADR falls -4.1460 percent for June 15 -

Autolus Therapeutics Plc Upcoming and Recent Events

Earnings reports are used by Autolus Therapeutics to provide an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Every quarterly earnings report provides investors with three things: an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Autolus Therapeutics previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
Upcoming Quarterly Report5th of August 2021
Next Earnings Report4th of November 2021
Next Fiscal Quarter End30th of June 2021
Next Fiscal Year End3rd of March 2022
Last Quarter Report31st of March 2021
Last Earning Announcement30th of June 2020

Autolus Largest EPS Surprises

Earnings surprises can significantly impact Autolus Therapeutics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Fiscal Date
Estimated EPS
Reported EPS
View All Earnings Estimates

Autolus Therapeutics SEC Filings

SEC filings are important regulatory documents required of all public companies to provide to potential investors. Autolus Therapeutics prospectus issued under the guidelines of SEC is a legal declaration of facts and statements to ensure that Autolus Therapeutics investors are not misled. SEC filings are required by law to meet strict transparency standards and other important legal constraints. Although many companies may choose careful wording to disguise some material information, SEC filings make crucial Autolus Therapeutics Plc specific information freely available to individual and institutional investors to make a timely investment decision.
6th of May 2021
Other Events
19th of April 2021
Other Events
17th of February 2021
Unclassified Corporate Event
16th of February 2021
Unclassified Corporate Event
12th of February 2021
Unclassified Corporate Event
11th of February 2021
Other Events
8th of January 2021
Unclassified Corporate Event
7th of December 2020
Other Events

Autolus Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Autolus Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Autolus Therapeutics Plc backward and forwards among themselves. Autolus Therapeutics' institutional investor refers to the entity that pools money to purchase Autolus Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Capital World InvestorsCommon SharesM16.9 M
Polygon Management LtdCommon Shares2.4 M14 M
Capital International InvestorsCommon Shares2.3 M13 M
Deerfield Management Company Lp Series CCommon Shares2.1 M12.3 M
Opaleye Management IncCommon Shares2.1 M12.1 M
Fmr LlcCommon Shares2.1 M11.9 M
Schroder Investment Management GroupCommon Shares1.7 M9.6 M
Note, although Autolus Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Autolus Market Capitalization

The company currently falls under 'Small-Cap' category with current market capitalization of 522.52 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Autolus Therapeutics's market, we take the total number of its shares issued and multiply it by Autolus Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Autolus Profitablity

Autolus Therapeutics' profitability indicators refer to fundamental financial ratios that showcase Autolus Therapeutics' ability to generate income relative to its revenue or operating costs. If, let's say, Autolus Therapeutics is currently losing money, the management's focus should be on how to reverse that trend. However, when revenue exceeds expenses, Autolus Therapeutics' executives or investors may be in less hurry to break that information down - which is where profitability analysis comes into play. Gaining a greater understanding of Autolus Therapeutics' profitability requires more research than a typical breakdown of Autolus Therapeutics' financial statements. By doing a profitability analysis, companies can identify areas needing attention, and investors can make a profitable trade.
Last ReportedProjected for 2021
Return on Average Assets(0.45) (0.48) 
Return on Average Equity(0.57) (0.62) 
Return on Invested Capital(1.29) (1.40) 
Return on Sales(96.94) (99.50) 

Management Efficiency

The entity has return on total asset (ROA) of (22.27) % which means that it has lost $22.27 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (29.62) %, meaning that it created substantial loss on money invested by shareholders. Autolus Therapeutics management efficiency ratios could be used to measure how well autolus therapeutics plc manages its routine affairs as well as how well it operates its assets and liabilities. The value of Return on Average Assets is estimated to pull down to -0.48. The value of Return on Average Equity is estimated to pull down to -0.62. Autolus Therapeutics Assets Non Current are relatively stable at the moment as compared to the past year. The company's current value of Assets Non Current is estimated at 104.93 Million. Goodwill and Intangible Assets is expected to hike to about 162.2 K this year, although the value of Current Assets will most likely fall to nearly 194.3 M.
Last ReportedProjected for 2021
Book Value per Share 4.07  4.49 
Enterprise Value over EBIT(2.00) (2.16) 
Enterprise Value over EBITDA(2.13) (2.30) 
Price to Book Value 2.23  2.60 
Tangible Assets Book Value per Share 5.70  6.57 
Enterprise Value341.9 M426.2 M
Tangible Asset Value294.1 M264.8 M

Technical Drivers

As of the 19th of June, Autolus Therapeutics shows the Mean Deviation of 4.04, downside deviation of 4.58, and Risk Adjusted Performance of 0.0407. Autolus Therapeutics Plc technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Put another way, you can use this information to find out if the firm will indeed mirror its model of historical prices and volume momentum, or the prices will eventually revert. We were able to interpolate and analyze data for nineteen technical drivers for Autolus Therapeutics Plc, which can be compared to its rivals. Please confirm Autolus Therapeutics Plc variance, value at risk, as well as the relationship between the Value At Risk and skewness to decide if Autolus Therapeutics Plc is priced correctly, providing market reflects its regular price of 7.57 per share. Given that Autolus Therapeutics has jensen alpha of 0.4199, we suggest you to validate Autolus Therapeutics Plc's prevailing market performance to make sure the company can sustain itself at a future point.

Autolus Therapeutics Plc Price Movement Analysis

Illegal number of arguments. The output start index for this execution was zero with a total number of output elements of zero. The Exponential Moving Average is calculated by weighting recent values of Autolus Therapeutics Plc more heavily than older values. View also all equity analysis or get more info about exponential moving average overlap studies indicator.

Autolus Therapeutics Predictive Daily Indicators

Autolus Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Autolus Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Autolus Therapeutics Forecast Models

Autolus Therapeutics time-series forecasting models is one of many Autolus Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Autolus Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

About Autolus Therapeutics Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Autolus Therapeutics stock is reacting to, or reflecting on a current stock market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Autolus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual stock such as Autolus Therapeutics. By using and applying Autolus Stock analysis, traders can create a robust methodology for identifying Autolus entry and exit points for their positions.
Last ReportedProjected for 2021
EBITDA Margin(93.64) (96.11) 
Gross Margin 0.90  0.89 
Profit Margin(82.85) (85.03) 
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. Autolus Therapeutics plc was founded in 2014 and is headquartered in London, the United Kingdom. Autolus Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 376 people.

Current Autolus Analysis - Recommendations

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Autolus analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Autolus analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
Target PriceAdvice# of Analysts
Autolus Therapeutics Plc current and past analyst recommendations published by a number of research institutions as well as average analyst consensus.
Most Autolus analysts issue ratings four times a year, at intervals of three months. Ratings are usually accompanied by a target price to helps potential investors understand Autolus stock's fair price compared to its market value. Analysts arrive at stock ratings after researching public financial statements of Autolus Therapeutics Plc, talking to its executives and customers, or listening to Autolus conference calls.
Autolus Analyst Advice Details

Autolus Stock Analysis Indicators

Autolus Therapeutics Plc stock analysis indicators help investors evaluate how Autolus Therapeutics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Autolus Therapeutics shares will generate the highest return on investment. By understating and applying Autolus Therapeutics stock analysis, traders can identify Autolus Therapeutics position entry and exit signals to maximize returns.
Quick Ratio10.32
Fifty Two Week Low4.60
Shares Short Prior Month1.47M
Average Daily Volume Last 10 Day3.53M
Average Daily Volume In Three Month1.36M
Shares Percent Shares Out3.17%
Forward Price Earnings-3.88
Float Shares33.9M
Fifty Two Week High17.19
Enterprise Value To Ebitda-1.20
Fifty Day Average6.25
Two Hundred Day Average7.20
Enterprise Value To Revenue76.88
Please continue to Trending Equities. Note that the Autolus Therapeutics Plc information on this page should be used as a complementary analysis to other Autolus Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Shere Portfolio module to track or share privately all of your investments from the convenience of any device.

Complementary Tools for Autolus Therapeutics Stock analysis

When running Autolus Therapeutics Plc price analysis, check to measure Autolus Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Autolus Therapeutics is operating at the current time. Most of Autolus Therapeutics' value examination focuses on studying past and present price action to predict the probability of Autolus Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Autolus Therapeutics' price. Additionally, you may evaluate how the addition of Autolus Therapeutics to your portfolios can decrease your overall portfolio volatility.
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
ETF Directory
Find actively-traded Exchange Traded Funds (ETF) from around the world
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Portfolio File Import
Quickly import all of your third-party portfolios from your local drive in csv format
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
The market value of Autolus Therapeutics Plc is measured differently than its book value, which is the value of Autolus that is recorded on the company's balance sheet. Investors also form their own opinion of Autolus Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Autolus Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Autolus Therapeutics' market value can be influenced by many factors that don't directly affect Autolus Therapeutics Plc underlying business (such as pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Autolus Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Autolus Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Autolus Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.